BRWA
CPRX

B. Riley Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

B. Riley Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-21,373
Closed -$354K – 1555
2023
Q1 		$354K Sell
21,373
-4,196
-16% -$69.2K 0.01% 976
2022
Q4 		$476K Buy
+25,569
New +$394K 0.01% 804
2014
Q3 		– Sell
-2,000
Closed -$5.06K – 878
2014
Q2 		$5.06K Buy
+2,000
New +$4.27K ﹤0.01% 2042

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

B. Riley Wealth Advisors's CPRX Position: Q2 2023 in Review

B. Riley Wealth Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2023, closing a stake of 21,373 shares — an estimated $354K sold.

B. Riley Wealth Advisors first reported a position in CPRX in Q2 2014 and held it in 3 quarters. The position peaked at $476K in Q4 2022. 248 funds tracked by Wall St. Rank hold CPRX as of Q2 2023.

  • B. Riley Wealth Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 21,373 Catalyst Pharmaceutical shares in Q2 2023, an estimated $354K.
  • B. Riley Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q2 2014 and held it in 3 quarters.
  • B. Riley Wealth Advisors's Catalyst Pharmaceutical position peaked at $476K in Q4 2022.
  • 248 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2023.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2023, filed 27 Jul 2023.